Background: Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin identified and plays an essential role in the maintenance of glucose tolerance in healthy humans. Until recently GIP had not been developed as a therapeutic and thus has been overshadowed by the other incretin, glucagon-like peptide 1 (GLP-1), which is the basis for several successful drugs to treat diabetes and obesity. However, there has been a rekindling of interest in GIP biology in recent years, in great part due to pharmacology demonstrating that both GIPR agonism and antagonism may be beneficial in treating obesity and diabetes. This apparent paradox has reinvigorated the field, led to new lines of investigation, and deeper understanding of GIP.
Scope Of Review: In this review, we provide a detailed overview on the multifaceted nature of GIP biology and discuss the therapeutic implications of GIPR signal modification on various diseases.
Major Conclusions: Following its classification as an incretin hormone, GIP has emerged as a pleiotropic hormone with a variety of metabolic effects outside the endocrine pancreas. The numerous beneficial effects of GIPR signal modification render the peptide an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, drug-induced nausea and both bone and neurodegenerative disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.molmet.2025.102118 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies.
Iran J Pharm Res
October 2024
Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Context: Dipeptidyl peptidase 4 (DPP-4) is a serine exopeptidase enzyme that hydrolyzes the amide bond at the N-terminal of peptides. This enzyme converts incretins, such as glucagon-like peptide I and glucose-dependent insulinotropic peptide, into their inactive forms, thereby preventing them from stimulating insulin secretion. Numerous studies have confirmed the role of DPP-4 in the pathophysiology of type 2 diabetes, leading to the development of various DPP-4 inhibitors.
View Article and Find Full Text PDFThe effects of GIP, GLP-1 and GLP-2 on markers of bone turnover: a review of the gut-bone axis.
J Endocrinol
March 2025
F Knop, Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Kobenhavn, Denmark.
Bone is a dynamic tissue continuously undergoing remodelling processes of resorption and formation to maintain bone mass and health. Food intake and the release of the gut-derived incretin hormones including glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) as well as its 'sister hormone' glucagon-like peptide 2 (GLP-2), appear to regulate bone turnover processes in the postprandial state as part of the so-called gut-bone axis. The effects of these gut hormones on bone metabolism depend on their circulating concentrations.
View Article and Find Full Text PDFCorticosteroid Administration Enhances the Glycemic, Insulinemic, and Incretin Responses to a High-Protein Mixed Meal in Adult Horses.
J Vet Intern Med
March 2025
The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA.
Background: Corticosteroids are used routinely in horses and induce insulin dysregulation (ID). Nutrition is important for ID management and includes low nonstructural carbohydrate (NSC) diets and, often, high-protein ration balancers (RB). Insulin and incretin secretion increase after high-protein meals; corticosteroids may influence these effects.
View Article and Find Full Text PDFEpicardial Adipose Tissue As Target of the Incretin-Based Therapies in Cardio-Metabolic Pathologies: A Narrative Review.
Can J Physiol Pharmacol
March 2025
University of Medicine and Pharmacy Victor Babes Timisoara, Pathophysiology, Timisoara, Romania;
The epicardial adipose tissue (EAT) serves in physiological conditions as a mechanical and thermal myocardial protective layer, as well as a readily available lipid-storage unit. In pathological conditions, EAT expansion becomes deleterious and is currently recognized as an independent risk factor for the progression of cardiovascular diseases. The EAT phenotypic shift from protective to pro-inflammatory/pro-oxidant is facilitated by the presence of metabolic diseases (obesity, metabolic syndrome, and diabetes), which further increase its expansion and dysregulation, favor the occurrence of complications (mainly atrial fibrillation), and promote progression towards heart failure.
View Article and Find Full Text PDF[Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?].
Nervenarzt
March 2025
Centre for Research in Eating and Weight Disorders (CREW), Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 16 De Crespigny Park, SE5 8AB, London, Großbritannien.
Albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, orforglipron and semaglutide are glucagon-like peptide‑1 (GLP-1) receptor agonists. Tirzepatide targets not only GLP‑1 but also glucose-dependent insulinotropic peptide (GIP) receptors and retatrutide is a triple GLP‑1, GIP and glucagon receptor agonist. The GLP‑1 receptor agonists increase insulin release but suppress glucagon release.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!